-- E.J. Mundell
TUESDAY, April 16 (HealthDay News) -- In an effort to help curb
the epidemic of prescription painkiller abuse, the U.S. Food and
Drug Administration on Tuesday said it is approving new labeling
for a reformulated version of Oxycontin that its maker claims will
be harder to abuse.
The agency also noted that the original form of the powerful
painkiller has been withdrawn from the market because it is easier
to abuse than the newer formulation.
"Accordingly, the agency will not accept or approve any abbreviated new drug applications (generics) that rely upon the approval of original OxyContin," the FDA added in a news release issued late Tuesday.
Prescription painkiller abuse continues to be a major problem
across the United States. According to a report issued in January
by the U.S. Substance Abuse and Mental Health Services
Administration (SAMHSA), some 22 million Americans -- 2 percent of
the population -- have misused prescription painkillers since
Oxycontin (oxycodone hydrochloride controlled-release) already
has Schedule II status as a potentially harmful and
restricted-access narcotic, based on an FDA review. In January, an
agency advisory panel voted to move other hydrocodone-containing
painkillers such as Vicodin and Percocet to the same status.
One other way to rein in rampant abuse of precription narcotics
is to develop formulations that are more difficult to break down
The original form of Oxycontin, first approved in 1995, "was
abused, often following manipulation intended to defeat its
extended-release properties," the FDA explained. "Such manipulation
causes the drug to be released more rapidly, which increases the
risk of serious adverse events, including overdose and death."
The new, "abuse-deterrent" version was approved in 2010 after
being developed by maker Purdue Pharma, and the company stopped
shipments of the older version of Oxycontin to pharmacies in August
of that year.
The new version is "more difficult to crush, break or dissolve,"
the FDA said, and it forms a thick, sticky gel that resists being
used as an injection. It is also more difficult to manipulate the
drug so it can be snorted, the agency said.
"The reformulated product also may reduce incidents of therapeutic misuse, such as crushing the product to sprinkle it onto food or to administer it through a gastric tube," the agency noted.
"The development of abuse-deterrent opioid analgesics is a public health priority for the FDA," Dr. Douglas Throckmorton, deputy director for regulatory programs in the FDA's Center for Drug Evaluation and Research, said in the agency's news release. "While both original and reformulated OxyContin are subject to abuse and misuse, the FDA has determined that reformulated OxyContin can be expected to make abuse by injection difficult and expected to reduce abuse by snorting compared to original OxyContin."
The FDA notes that postmarketing studies looking at the abuse
potential of the new formulation are ongoing.
Find out more about prescription painkiller abuse at
U.S Centers for Disease Control and
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.